Gotham Asset Management’s Theravance Biopharma TBPH Stock Holding History

Gotham Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$734K	Buy	45,212 +22,532	+99%	+$399K	﹤0.01%	1393
2025 Q4	$424K	Buy	+22,680	New	+$376K	﹤0.01%	1478
2017 Q1	–	Sell	-9,571	Closed	-$305K	–	1102
2016 Q4	$305K	Buy	+9,571	New	+$297K	﹤0.01%	808
2016 Q1	–	Sell	-69,582	Closed	-$733K	–	1074
2015 Q4	$733K	Buy	+69,582	New	+$1.1M	0.01%	647

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gotham Asset Management's TBPH Position: Q1 2026 in Review

Gotham Asset Management increased its Theravance Biopharma (TBPH) stake by 99% in Q1 2026, buying an estimated $399K and bringing the position to 45,212 shares worth $734K. The position accounts for ﹤0.01% of the portfolio, ranked #1393.

Gotham Asset Management first reported a position in TBPH in Q4 2015 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

Gotham Asset Management held 45,212 shares of Theravance Biopharma worth $734K as of Q1 2026.
Gotham Asset Management bought 22,532 Theravance Biopharma shares in Q1 2026, an estimated $399K.
Theravance Biopharma made up ﹤0.01% of Gotham Asset Management's portfolio in Q1 2026, its #1393 holding.
Gotham Asset Management first reported a position in Theravance Biopharma in Q4 2015 and has held it in 4 quarters since.
173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Gotham Asset Management's 13F filing for Q1 2026, filed 15 May 2026.